Limited understanding of protein‑protein interactions hindered drug target validation.

Developed a high‑throughput FRET assay, accelerating target validation by 40%.

Low‑throughput sequencing yielded incomplete genomic maps.

Implemented long‑read sequencing pipeline, increasing genome assembly contiguity by 3‑fold.

Inconsistent cell culture conditions caused variable assay results.

Standardized SOPs and automated media preparation, reducing variability by 25%.

Manual data entry introduced errors in clinical trial datasets.

Created an automated data capture system, eliminating entry errors and cutting processing time in half.

Research findings were published in low‑impact journals.

Led a collaborative study published in Nature, raising lab visibility and funding prospects.